The Japanese government on March 7 announced new NHI prices for the FY2025 drug price revision, effective April 1. With…
BUSINESS
BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
Bristol Myers Squibb said on January 6 that it has appointed Eli Lilly veteran Hidehito Katsuma as the new president of its Japan arm. He is taking over the helm from Steve Sugino, who has assumed the role of general…
To read the full story
Related Article
BUSINESS
- Specialist Sees Promise in Bispecific Engagers for MM Therapy
March 31, 2025
- Hematologist Praises Benefit of Fixed-Duration FL Treatment with Lunsumio
March 31, 2025
- Japan Approves Tablet Form of Chugai’s SMA Med Evrysdi
March 31, 2025
- Nippon Shinyaku Files BPDCN Drug in Japan
March 31, 2025
- Eisai Hands Over Rights to Pariet in China to CBC Group
March 31, 2025
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…